Pfizer study shows Xeljanz on par with Humira for treating rheumatoid arthritis
Pfizer Inc. recently published noninferiority results from its study of Xeljanz, a twice-daily monotherapy to be used in combination with methotrexate in treating patients with moderate to severe rheumatoid arthritis. Read More »
Lexicon releases results from diabetes drug studies
Lexicon Pharmaceuticals Inc. recently presented its two sotagliflozin studies, inTandem1 and inTandem2, at the 77th American Diabetes Association Scientific Sessions in San Diego, California. Read More »
QuVa Pharma rallies to address antacid shortage
Addressing a recently reported nationwide antacid scarcity, QuVa Pharma Inc. — specializing in critical drug shortage products — has rallied with supplies of its own pharmaceutical quality sodium bicarbonate formulation at the ready for U.S. hospital distribution. Read More »
Pfizer meningitis drug gains European approval for young patients
Trumenba, Pfizer’s branded vaccine against certain forms of meningococcal disease, officially won approval from the European Commission for patients aged 10 years and up, representing progress for protection in the young adult demographic. Read More »
Texas Pharmacy Association receives grant to create community health care platform
The Texas Pharmacy Association (TPA) has received a grant from the Community Pharmacy Foundation and Texas Department of State Health Services that will allow the association to create community-based health care provider digital linkages with pharmacists. Read More »
CMS approves McKesson Specialty Health's iKnowMed
The Centers for Medicare and Medicaid Services recently authorized Texas-based McKesson Specialty Health as a Qualified Clinical Data Registry, rendering it eligible to participate in the Merit-Based Incentive Payment System for 2017. Read More »
Pfizer furthers partnership for affordable contraception in developing countries
Mutual recommitment to a partnership between Pfizer and two U.S. foundations has successfully ensured continued access to Pfizer’s Sayana Press contraceptive for women in the world’s poorest nations. Read More »
Pfizer, Celltrion present data on Inflectra at 12th ECCO Congress
Pfizer Inc. and Celltrion Healthcare presented data at the 12th Congress of the European Chron’s and Colitis Organisation showing Inflectra (infliximab CT-P13) delivers similar efficacy and safety as Remicade (infliximab) for treating Chron’s Disease. Read More »
Pfizer plans Phase 3 study of Clostridium difficile vaccine
Pfizer Inc. recently shared positive data from its Phase 2 study examining Clostridium difficile (C. difficile) vaccine candidate, PF-06425090, a product created to help prevent C. difficile infection (CDI), which can include life-threatening diarrhea and pseudomembranous colitis. Read More »
Pfizer's Xeljanz receives positive opinion from European committee
Pfizer Inc. recently announced that its Xeljanz drug for treating moderate to severe active rheumatoid arthritis (RA) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Read More »
Bavencio gains FDA approval for intravenous use
Pfizer Inc. and EMD Serono, Merck KHaA’s biopharmaceutical arm in the United States and Canada, recently announced that Bavencio was approved by the Food and Drug Administration for intravenous use. Read More »
Abbott's RealTime Zika Test approved for use in U.S.
Abbott recently announced that its molecular test, the Abbott RealTime Zika Test, has been authorized by the U.S. Food and Drug Administration (FDA). Read More »
Takeda taps Biologics as specialty provider for cancer drug
Biologics Inc., a McKesson Specialty Health company, has been selected by Takeda Pharmaceutical Co. to be a “specialty pharmacy provider” for ALUNBRIG, a Takeda-manufactured drug for anaplastic lymphoma kinase positive metastatic non-small cell lung cancer. Read More »
Advanced Pharma/Avella recalls 'latex free' products
Advanced Pharma Inc., which does business as Avella of Houston, is voluntarily recalling unexpired sterile injectable products labeled "latex free" that were produced at the company’s Houston location between Sep. 1, 2016 and Feb. 16, 2017. Read More »
BAVENCIO receives FDA approval for advanced bladder cancer treatment
EMD Serono has received Food and Drug Administration approval of BAVENCIO (avelumab) as a treatment for locally advanced or metastatic urothelial carcinoma. Read More »
Pfizer's inotuzumab ozogamicin accepted for priority review
The U.S. Food and Drug Administration has accepted Pfizer's Biologics License Application for inotuzumab ozogamicin. Read More »
Pfizer releases results from ORAL Strategy study of Xeljanz
Pfizer Inc. recently released top-line results for ORAL Strategy, a Phase 3B/4 study of XELJANZ (tofacitinib citrate) 5mg twice daily in the treatment of moderate to severe rheumatoid arthritis. Read More »
Biologics chosen as specialty pharmacy provider for ZEJULA
Biologics Inc., a McKesson Specialty Health oncology pharmacy services company, has been chosen by Tesaro Inc. to provide its new drug. Read More »
FDA grants priority review to carcinoma drug
EMD Serono, the biopharmaceutical business of Merck KGaA and Pfizer Inc., recently announced that the Biologics License Application (BLA) for their avelumab drug was accepted for Priority Review by the U.S. Food and Drug Administration (FDA). Read More »